HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS – Free Report) in a report issued on Monday,Benzinga reports. The firm currently has a $40.00 price target on the stock.
Separately, Canaccord Genuity Group reduced their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.
Read Our Latest Report on GHRS
GH Research Trading Down 0.2 %
Institutional Inflows and Outflows
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its position in shares of GH Research PLC (NASDAQ:GHRS – Free Report) by 1.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.
About GH Research
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Further Reading
- Five stocks we like better than GH Research
- Trading Halts Explained
- Sizing Up a New Opportunity for NVIDIA Investors
- What Are Dividend Challengers?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.